Insiders FibroGen, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
1.17 ^USD	+4.46%		+18.87%	+32.01%

Apr. 24	FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting	CI
Apr. 15	Faron Pharmaceuticals reappoints former finance chief on interim basis	AN

Faron Pharmaceuticals reappoints former finance chief on interim basis	Apr. 15	AN
FibroGen Names Deyaa Adib Chief Medical Officer	Mar. 11	MT
FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer	Mar. 11	CI
FibroGen Names Interim Chief Executive Thane Wettig as CEO	23-10-06	MT
FibroGen, Inc. Appoints Thane Wettig as a Member of the Board	23-10-06	CI
FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer	23-10-06	CI
Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023	23-09-06	CI
Fibrogen, Inc. Announces Chief Executive Officer Changes	23-07-25	CI
FibroGen Names Thane Wettig as Interim CEO	23-07-25	MT
Insider Sell: Fibrogen	23-06-16	MT
Insider Sell: Fibrogen	23-04-06	MT
Insider Sell: Fibrogen	23-04-06	MT
Insider Sell: Fibrogen	23-03-13	MT
FibroGen, Inc. Appoints Juan Graham as Chief Financial Officer	21-11-09	CI
Insider Sell: Fibrogen	21-09-17	MT
FibroGen, Inc. Appoints John Hunter as Chief Scientific Officer	21-07-12	CI
Insider Trends: 90-Day Insider Buying Trend at FibroGen Slowed with Sale of Shares	21-06-17	MT
Fibrogen, Inc Announces Resignation of Kurkijärvi as Director, Effect from June 30, 2021	21-04-13	CI
Fibrogen, Inc. Appoints Thane Wettig as Newly Created Position of Chief Commercial Officer	21-03-01	CI
Insider Trends: FibroGen Insider Disposition Interrupting 90-Day Buy Trend	20-12-17	MT

No results for this search